Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 23,858

Document Document Title
WO/2018/170335A1
The present disclosure provides distinct therapeutic populations of cells that form a pharmaceutical composition useful in hematopoietic stem/progenitor cell transplant. For example, the present disclosure provides a therapeutic populati...  
WO/2018/169804A1
A neuromuscular toxin is for use in treating abnormalities of the first metatarsophalangeal joint of the foot of a mammal by administering an amount of neuromuscular toxin effective to treat the abnormalities via intramuscular injection ...  
WO/2018/164251A1
The present invention addresses the problem of providing a novel composition for improving physical strength. According to the present invention, a composition for improving physical strength which contains milk protein as an active ingr...  
WO/2018/162617A1
The present invention relates to AceFaPC (1-Acetyl-2-Fatty acyl-glyceroPhosphoCholine) for use in the prevention and treatment of diseases associated with an acetylcholine deficiency. The invention also relates to the AceFaPC molecule in...  
WO/2018/164221A1
The purpose of the present invention is to provide: a composition for inhibiting myofibrosis, which contains, as an active ingredient, a component that can be safely ingested over a prolonged period of time; and a method for safely inhib...  
WO/2018/162931A1
The present invention provides a method for determining whether a patient will respond to treatment with a myostatin pathway inhibitor, the method comprising : (a) determining a level of myostatin and/or activin type II receptor (ActRII)...  
WO/2018/157258A1
A method of improving at least one of the following in an individual: lean mass, muscle strength, cognition, systemic inflammation levels, blood cholesterol levels, blood triglyceride levels and glucose tolerance is provided, comprising ...  
WO/2018/159852A1
The purpose of the present invention is to provide a curcumin-containing solid composition which can be used as a composition for treatment or prevention of disorders or symptoms in which intracellular absorption of curcumin is beneficia...  
WO/2018/154412A1
The present application provides materials and methods for treating a patient with one or more conditions or disorders associated with LAMA2, both ex vivo or in vivo. For example, the present disclosure provides materials and methods for...  
WO/2018/157009A1
The invention related to polynucleotides comprising an open reading frame of linked nucleosides encoding therapeutic proteins or variant therapeutic proteins, isoforms thereof, functional fragments thereof, and fusion proteins comprising...  
WO/2018/154578A1
Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.  
WO/2018/151225A1
The muscle differentiation promoter according to the present invention includes oligo DNA having activity to promote muscle differentiation by being applied to cells or to an individual. The oligo DNA preferably includes a core base sequ...  
WO/2018/151841A1
Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are method...  
WO/2018/144677A1
Disclosed herein are methods of reducing muscle contraction in a diaphragm or peripheral muscle(s) of a patient sufficient to permit a surgical procedure. The methods may comprise the step of administering an oxime or pharmaceutically ac...  
WO/2018/137483A1
A sustained-release nanoparticle for targeting a neurodegenerative disease, a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing and/or treating a neurodegen...  
WO/2018/140412A1
The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effecti...  
WO/2018/138646A1
The present invention relates to a fusion peptide comprising an active peptide portion and a carrier peptide portion. The present invention further relates to the use of such peptide as medicament, particularly for use in the prevention,...  
WO/2018/136943A1
Described herein are compositions comprising activators of TRP and ASIC channels that may be useful to improve or preserve exercise performance and exercise recovery.  
WO/2018/128587A1
Disclosed is an isolated variant of SMCHD1 peptide, or fragment thereof, comprising one or more mutation(s) that increases SMCHD1 activity in a cell compared to a cell with a wild- etype SMCHD1 peptide. Also disclosed are isolated nuclei...  
WO/2018/129395A1
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.  
WO/2018/129315A1
The invention relates to methods and compositions comprising a TRP channel or ASIC channel activator for preventing or treating a disease, disorder, or condition described herein.  
WO/2018/129434A1
The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrom...  
WO/2018/124292A1
Provided is a method for inducing skeletal muscle cells, the method comprising a step for introducing an MyoD family gene or an expression product thereof, and an Myc family gene or an expression product thereof into mammalian somatic ce...  
WO/2018/120920A1
Disclosed is a cisatracurium besilate lyophilized powder-injection preparation for intravenous administration, which is made of the following components in parts by weight: 1-5 parts of cisatracurium besilate, 10-40 parts of dimyristoylp...  
WO/2018/124011A1
The purpose of the present invention is to provide a motor control function improving agent that improves motor control functions which have deteriorated due to aging or fatigue, and a method for evaluating or selecting the motor control...  
WO/2018/124258A1
The present invention can provide: a prophylactic or ameliorating/therapeutic agent for chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, which contains a processed product of Japanese horseradish (wasabi) as an acti...  
WO/2018/118627A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.  
WO/2018/118662A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.  
WO/2018/112541A1
The present invention relates to methods of increasing vascular density and/or blood flow in tissue of a subject, and to increasing exercise capacity of a subject, the methods include administering to a subject an effective amount of an ...  
WO/2018/118599A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.  
WO/2018/118957A1
This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.  
WO/2018/108991A2
The present invention is directed to a method of treating an amyloid-β peptide disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound that enhances mitoc...  
WO/2018/108991A3
The present invention is directed to a method of treating an amyloid-β peptide disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound that enhances mitoc...  
WO/2018/103119A1
The present invention provides a hydrobromate of methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazole[1,2-a][1 ,4]benzodiazepine-4-yl]propionate and related crystal forms and preparation method and use thereof. The hydrobromate has...  
WO/2018/106339A1
Disclosed herein are compositions and methods for use in conjunction with surgical treatments related to tendon repair. Embodiments disclosed herein can locally reduce muscular activity and thereby reduce tension, for example after surgi...  
WO/2018/105550A1
Provided is an amyotrophy inhibiting composition that comprises one or more kinds of peptides as active ingredient(s), said peptides being selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP and ...  
WO/2018/105630A1
The present invention pertains to: a drug for preventing and/or treating cognitive dysfunction and/or a neurodegenerative disease accompanied by accumulation of prionoids, said drug comprising hemagglutinating virus of Japan envelope as ...  
WO/2018/099946A1
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I), wherein one of T1 and T2 is OR1 or OR2; and the other of T1 and T2 i...  
WO/2018/101398A1
The present invention provides a pharmaceutical composition for use in the treatment or prevention of inflammatory bowel disease (IBD). More particularly, the present invention provides a pharmaceutical composition that contains apelin o...  
WO/2018/096100A1
The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prio...  
WO/2018/097733A3
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...  
WO/2018/097733A2
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...  
WO/2018/091688A1
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...  
WO/2018/090792A1
Disclosed are a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, a preparation and the use thereof in the preparation of a drug for treating diseases, disorders or conditions benefiting from the ...  
WO/2018/091691A1
The present invention relates to LSD1 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a diseas...  
WO/2018/091689A1
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...  
WO/2018/088501A1
Provided is a method for inducing differentiation of pluripotent stem cells into somatic cells using a medium containing heparin binding growth factor, characterized by comprising contacting starting cells with a conjugate in which a lam...  
WO/2018/083271A1
The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selectin...  
WO/2018/079719A1
The purpose of the invention is to provide a composition that has high biological safety and contributes to the activation of PGC-1α. Also, the purpose of the invention is to provide a use for said composition for activating PGC-1α and...  
WO/2018/078134A1
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.  

Matches 1 - 50 out of 23,858